GlassScriptPhysician profile
Michael D Herndon
NPI 1508859588
$3,838.06
in general payments reported to CMS, 2019-2025
25 companies · $575 in 2025
The $575 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $420 · 2021: $712 · 2022: $517 · 2023: $606 · 2024: $716 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,896.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $868.92 | 2021-2025 | |
| Novo Nordisk INC | $742.42 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $365.31 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $304.91 | 2021-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.69 | 2020-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $218.60 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amarin Pharma, INC. | $132.18 | 2020-2021 | |
| Lilly USA, LLC | $121.04 | 2020-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $113.40 | 2019-2021 | |
| Exact Sciences Corporation | $105.71 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $96.77 | 2021-2024 | Repatha, Otezla |
| Pfizer INC. | $74.92 | 2019-2025 | |
| Arbor Pharmaceuticals, INC. | $70.56 | 2019-2021 | |
| Eisai INC. | $62.12 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $47.03 | 2025 | Nuzyra, Xhance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $43.46 | 2019-2023 | Trintellix |
| Axsome Therapeutics, INC. | $36.58 | 2024 | Auvelity |
| Dexcom, INC. | $33.82 | 2021-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $28.77 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.49 | 2019 | |
| Merck Sharp & Dohme LLC | $21.51 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.04 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.37 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.81 | 2024 | Xifaxan |
| Allergan, INC. | $12.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Herndon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.